Anti-immunoglobulin E in the treatment of refractory atopic dermatitis: Anti-immunoglobulin E in the treatment of refractory AD
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease affecting > 10% of children and 1-3% of adults, and can cause significant morbidity. The incidence of AD seems to be increasing. Omalizumab, a monoclonal antibody, has recently been suggested as a potential new systemic treatment for patients with recalcitrant AD with elevated IgE levels, based on its efficacy in treating asthma and allergic rhinitis. We report a study of 10 patients with AD (aged 19-35 years) who received anti-IgE treatment for persistent asthma. All patients, regardless of IgE value, were treated with a fixed schedule of eight cycles of omalizumab 300 mg administered subcutaneously at intervals of 2 weeks. Eczema symptoms were scored at baseline and after 2, 4 and 6 months of treatment. There was a steady improvement in the objective SCORAD (SCORing Atopic Dermatitis), with significantly lower scores observed at the 6-month evaluation. At 2 months after the end of treatment, two patients had a very good result (SCORAD reduction of > 50%), five patients had a satisfactory result (reduction of 25-50%), and three patients had no clinically relevant result (reduction of 25-50%). No patient had worsening of the AD (increase of > 25% in SCORAD), and once a clinical improvement occurred, none of the patients experienced worsening of their eczema symptoms while on omalizumab. With the caveats of the financial expense and unknown long-term risks of malignancy associated with omalizumab, this drug should be considered for treatment-resistant patients with AD, particularly patients with high IgE level whose symptoms are not controlled by routine therapies. Omalizumab has proven useful in treating asthma, but it may also prove valuable for other conditions, such as allergic rhinitis, food allergies, chronic urticaria, and AD, as shown by the present study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akdis, C. A., Akdis, M., Bieber, T., Bindslev-Jensen, C., Boguniewicz, M., Eigenmann, P., Hamid, Q., Kapp, A., Leung, D. Y. M., Lipozencic, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.03.045 · Cited by 460
Epidemiology of atopic dermatitis
Larsen, F. S., & Hanifin, J. M. (2002) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(03)00066-3 · Cited by 310
Treatment of recalcitrant atopic dermatitis with omalizumab
Lane, J. E., Cheyney, J. M., Lane, T. N., Kent, D. E., & Cohen, D. J. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.09.030 · Cited by 188
Failure of omalizumab for treatment of severe adult atopic dermatitis
Krathen, R. A., & Hsu, S. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.02.014 · Cited by 172
Cited by
Suárez-Fariñas, M., Dhingra, N., Gittler, J., Shemer, A., Cardinale, I., de Guzman Strong, C., Krueger, J. G., & Guttman-Yassky, E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.046 · Cited by 483
Fajt, M. L., & Wenzel, S. E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1871 · Cited by 353
Omalizumab for atopic dermatitis: case series and a systematic review of the literature
Holm, J. G., Agner, T., Sand, C., & Thomsen, S. F. (2017) · International Journal of Dermatology · doi:10.1111/ijd.13353 · Cited by 71
Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab
Zink, A., Gensbaur, A., Zirbs, M., Seifert, F., Suarez, I., Mourantchanian, V, Weidinger, S., Mempel, M., Ring, J., & Ollert, M. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2165 · Cited by 67
“…reduction in IgE levels in AD (19), studies with omalizumab typically had very ambivalent re-sults: some showed a benefit for patients with AD (4, 5), some rejected this treatment approach (6, 7) and others discussed the high IgE level in AD as a possible limitation for a promising use of this…”
Metadata
- Authors
- Kim, D. H., Park, K. Y., Kim, B. J., Kim, M. N., & Mun, S. K.
- Venue
- Clinical and Experimental Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-10-22
- Volume
- 38
- Issue
- 5
- Pages
- 496-500
- ISSN
- 0307-6938 (ISSN-L)
- OpenAlex
- W1597018795
- Cited by
- 70
- References
- 4
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-immunoglobulin E in the treatment of refractory atopic dermatitis: Anti-immunoglobulin E in the treatment of refractory AD. https://app.cochat.ai/papers/10.1111/j.1365-2230.2012.04438.x
- The paper
- Kim, D. H., Park, K. Y., Kim, B. J., Kim, M. N., & Mun, S. K. (2013). Anti-immunoglobulin E in the treatment of refractory atopic dermatitis: Anti-immunoglobulin E in the treatment of refractory AD. Clinical and Experimental Dermatology. https://doi.org/10.1111/j.1365-2230.2012.04438.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.